Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

For BMS, Onglyza Disappoints And Health Care Reform Takes A Toll

This article was originally published in The Pink Sheet Daily

Executive Summary

The health care reform law, which will lower Bristol-Myers Squibb's sales by $350 million to $400 million this year, led the firm to revise earnings guidance.

You may also be interested in...



Novo Nordisk's GLP-1 Victoza Off To A Good Start

New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.

340B Entities Will Continue Fighting For Inpatient Drug Discounts

Issue is a top priority for Safety Net Hospitals for Pharmaceutical Access; provision to extend discounts to inpatient drugs was deleted from final health care reform bill.

J&J Braces For Health Care Reform Hit, But Can "Accommodate" Impact

J&J's 2010 sales will be $400 million to $500 million lower due to health care reform, although J&J didn't significantly lower 2010 earnings as a result.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel